Abstract

Research Article

Antimycolytic agents: fungistatic and fungicide

Gudisa Bereda*

Published: 06 May, 2022 | Volume 6 - Issue 1 | Pages: 001-009

Invasive fungal infections are described as a continuous and severe harm to human health and they are associated with at least 1.5 million deaths worldwide each year. Amphotericin B exerts its activity through hydrophobic interactions with cell membrane ergosterol, cause the rupturing or leakage of cell membrane. The antifungal azole medicine group is classified as imidazoles (clotrimazole, ketoconazole, miconazole) and triazoles (fluconazole, itraconazole, voriconazole, posaconazole, isavuconazole) that are named according to the number of nitrogen atoms in the azole ring. Flucytosine is a first-line treatment for the management of cryptococcal meningitis. The most routine adverse effects of fluconazole involve accelerated liver enzymes, gastrointestinal complaints, headache, and skin rash. If antacids, PPIs, H2 blockers administered together with ketoconazole medicines; they will reduce the blood levels of ketoconazole by increasing gastric pH because ketoconazole requires an acidic media for dissolution and systematic absorption. Griseofulvin ruptures mitotic spindle during metaphase by interacting with fungal microtubules-(-), fungal mitosis (metaphase arrest), adequate to block expansion of fungi (drug is static), preventing them from damaging.

Read Full Article HTML DOI: 10.29328/journal.adr.1001019 Cite this Article Read Full Article PDF

Keywords:

Antimycolytic; Fungistatic; Fungicide

References

  1. Amara AA. Improving Animal Immunity to Prevent Fungal Infections with Folk Remedies and Advanced Medicine. In Fungal Diseases in Animals. 2021;127-162.
  2. Watkinson SC. Physiology and adaptation. In The Fungi 2016 Jan 1;141-187.
  3. Dutt K. Role of Antifungal Drugs in Combating Invasive Fungal Diseases. High Value Fermentation Products: Human Health. 2019 Mar 12;1:103-44.
  4. Hubka V, Peano A, Cmokova A, Guillot J. Common and emerging dermatophytoses in animals: well-known and new threats. InEmerging and Epizootic Fungal Infections in Animals 2018;31-79.
  5. Pianalto KM, Alspaugh JA. New Horizons in Antifungal Therapy. J Fungi (Basel). 2016 Oct 2;2(4):26. doi: 10.3390/jof2040026. PMID: 29376943; PMCID: PMC5715934.
  6. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med. 2012 Dec 19;4(165):165rv13. doi: 10.1126/scitranslmed.3004404. PMID: 23253612.
  7. Pianalto KM, Alspaugh JA. New Horizons in Antifungal Therapy. J Fungi (Basel). 2016 Oct 2;2(4):26. doi: 10.3390/jof2040026. PMID: 29376943; PMCID: PMC5715934.
  8. Carmona EM, Limper AH. Overview of Treatment Approaches for Fungal Infections. Clin Chest Med. 2017 Sep;38(3):393-402. doi: 10.1016/j.ccm.2017.04.003. Epub 2017 May 31. PMID: 28797484.
  9. Shikanai-Yasuda MA. PARACOCCIDIOIDOMYCOSIS TREATMENT. Rev Inst Med Trop Sao Paulo. 2015 Sep;57 Suppl 19(Suppl 19):31-7. doi: 10.1590/S0036-46652015000700007. PMID: 26465367; PMCID: PMC4711189.
  10. Mendes RP, Cavalcante RS, Marques SA, Marques MEA, Venturini J, Sylvestre TF, Paniago AMM, Pereira AC, da Silva JF, Fabro AT, Bosco SMG, Bagagli E, Hahn RC, Levorato AD. Paracoccidioidomycosis: Current Perspectives from Brazil. Open Microbiol J. 2017 Oct 31;11:224-282. doi: 10.2174/1874285801711010224. PMID: 29204222; PMCID: PMC5695158.
  11. Mendes RP, Cavalcante RS, Marques SA, Marques MEA, Venturini J, Sylvestre TF, Paniago AMM, Pereira AC, da Silva JF, Fabro AT, Bosco SMG, Bagagli E, Hahn RC, Levorato AD. Paracoccidioidomycosis: Current Perspectives from Brazil. Open Microbiol J. 2017 Oct 31;11:224-282. doi: 10.2174/1874285801711010224. PMID: 29204222; PMCID: PMC5695158.
  12. Lenz KD, Klosterman KE, Mukundan H, Kubicek-Sutherland JZ. Macrolides: From Toxins to Therapeutics. Toxins (Basel). 2021 May 12;13(5):347. doi: 10.3390/toxins13050347. PMID: 34065929; PMCID: PMC8150546.
  13. Nasr G, Greige-Gerges H, Elaissari A, Khreich N. Liposomal membrane permeability assessment by fluorescence techniques: Main permeabilizing agents, applications and challenges. Int J Pharm. 2020 Apr 30;580:119198. doi: 10.1016/j.ijpharm.2020.119198. Epub 2020 Mar 10. PMID: 32169353.
  14. Drew RH. Polyenes for prevention and treatment of invasive fungal infections. InAntifungal therapy 2019 Mar 8; 155-175.
  15. Drew RH, Townsend ML, Pound MW, Johnson SW. Antifungal use in transplant recipients: Selection, administration, and monitoring. InAntifungal Therapy 2019 Mar 8;403-443.
  16. McKeny PT, Nessel TA, Zito PM. Antifungal antibiotics. StatPearls [Internet]. 2020 Sep 29.
  17. Kaushik A, Kest H. The Role of Antifungals in Pediatric Critical Care Invasive Fungal Infections. Crit Care Res Pract. 2018 Nov 22;2018:8469585. doi: 10.1155/2018/8469585. PMID: 30595916; PMCID: PMC6282141.
  18. Mourad A, Perfect JR. Tolerability profile of the current antifungal armoury. J Antimicrob Chemother. 2018 Jan 1;73(suppl_1):i26-i32. doi: 10.1093/jac/dkx446. PMID: 29304209; PMCID: PMC6636388.
  19. Karimzadeh I, Khalili H, Sagheb MM. Preventing or attenuating amphotericin B nephrotoxicity with dopamine receptor agonists: a literature review. Trends in Pharmaceutical Sciences. 2015 Sep 1;1(3):129-38.
  20. Bellmann R, Smuszkiewicz P. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection. 2017 Dec;45(6):737-779. doi: 10.1007/s15010-017-1042-z. Epub 2017 Jul 12. PMID: 28702763; PMCID: PMC5696449.
  21. Bustamante B, Hidalgo JA, Campos PE. Antifungal Drugs. InCurrent Progress in Medical Mycology 2017;29-89.
  22. Carreno JJ, Kenney RM, Lomaestro B. Vancomycin-associated renal dysfunction: where are we now? Pharmacotherapy. 2014 Dec;34(12):1259-68. doi: 10.1002/phar.1488. Epub 2014 Sep 15. PMID: 25220436.
  23. Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol. 2012 Sep;68(9):1243-55. doi: 10.1007/s00228-012-1259-9. Epub 2012 Mar 13. PMID: 22411630.
  24. Maloy JP. Characterization of an Intracellular Flagellar System in Pathogenic Burkholderia Species. University of California, Los Angeles; 2017.
  25. Abdelgadir HE. Eumycetoma and Plant-based Pharmacotherapy Candidates (Doctoral dissertation, University of Gezira).
  26. Odiba AS. Molecular profiling and phylogenetic analysis of the erg11 gene of fluconazole resistant strains of candida species isolated from humans and dogs of reproductive age (Doctoral dissertation, University of Nigeria, Nsukka).
  27. Ward NP, DeNicola GM. Sulfur metabolism and its contribution to malignancy. Int Rev Cell Mol Biol. 2019;347:39-103. doi: 10.1016/bs.ircmb.2019.05.001. Epub 2019 Jun 17. PMID: 31451216.
  28. Lewis RE, Fothergill AW. Antifungal agents. InDiagnosis and Treatment of Fungal Infections 2015;79-97.
  29. Carlsson M. Metabolic regulation and anticancer drug resistance in the yeast Saccharomyces cerevisiae. 2014 Aug 19.
  30. Makanjuola O, Bongomin F, Fayemiwo SA. An Update on the Roles of Non-albicansCandida Species in Vulvovaginitis. J Fungi (Basel). 2018 Oct 31;4(4):121. doi: 10.3390/jof4040121. PMID: 30384449; PMCID: PMC6309050.
  31. Yousfi H, Cassagne C, Ranque S, Rolain JM, Bittar F. Repurposing of Ribavirin as an Adjunct Therapy against Invasive Candida Strains in an In Vitro Study. Antimicrob Agents Chemother. 2019 Sep 23;63(10):e00263-19. doi: 10.1128/AAC.00263-19. PMID: 31307986; PMCID: PMC6761495.
  32. Turtle L, Hope W. Flucytosine (5-Fluorocytosine; 5-FC). InKucers’ The Use of Antibiotics 2017 Oct 2; 2919-2926.
  33. Nett JE, Andes DR. Antifungal Agents: Spectrum of Activity, Pharmacology, and Clinical Indications. Infect Dis Clin North Am. 2016 Mar;30(1):51-83. doi: 10.1016/j.idc.2015.10.012. Epub 2015 Dec 29. PMID: 26739608.
  34. Sleeper M. Equine cardiovascular clinical pharmacology. Equine Pharmacology. 2014 Sep 3:279.
  35. Chang YL, Yu SJ, Heitman J, Wellington M, Chen YL. New facets of antifungal therapy. Virulence. 2017 Feb 17;8(2):222-236. doi: 10.1080/21505594.2016.1257457. Epub 2016 Nov 7. PMID: 27820668; PMCID: PMC5354158.
  36. Spernovasilis N, Kofteridis DP. Pre-existing liver disease and toxicity of antifungals. J Fungi. 2018 Dec;4(4):133.
  37. Chastain DB, Franco-Paredes C, Stover KR. Addressing Antiretroviral Therapy-Associated Drug-Drug Interactions in Patients Requiring Treatment for Opportunistic Infections in Low-Income and Resource-Limited Settings. J Clin Pharmacol. 2017 Nov;57(11):1387-1399. doi: 10.1002/jcph.978. Epub 2017 Sep 8. PMID: 28884831.
  38. Shafiei M, Peyton L, Hashemzadeh M, Foroumadi A. History of the development of antifungal azoles: A review on structures, SAR, and mechanism of action. Bioorg Chem. 2020 Nov;104:104240. doi: 10.1016/j.bioorg.2020.104240. Epub 2020 Aug 28. PMID: 32906036.
  39. Gowda DV, Afrasim M, Meenakshi SI, Manohar M, Hemalatha S, Siddaramaiah H, Sathishbabu P, Rizvi SMD, Hussain T, Kamal MA. A Paradigm Shift in the Development of Anti-Candida Drugs. Curr Top Med Chem. 2019;19(28):2610-2628. doi: 10.2174/1568026619666191029145209. PMID: 31663480.
  40. Class IP, USPC A. Patent application title: COMPOSITIONS AND METHODS FOR TREATING FUNGAL INFECTIONS Inventors: James J. Collins (Newton, MA, US) James J. Collins (Newton, MA, US) Peter A. Belenky (Framingham, MA, US) Diogo M. Camacho (Framingham, MA, US).
  41. Nguyen Van Kinh MD, Le T, Cuc NT, Thuy PT, Hanh DT, Phuc PH, Chinh NT, Chi NH, Quang VM, Lam NT, Thuy CT. A Randomized, Open-Label, Comparative Study of the Effectiveness of Itraconazole versus Amphotericin B in the Induction Treatment of Penicilliosis in HIV-Infected Adults.
  42. Choi FD, Juhasz MLW, Atanaskova Mesinkovska N. Topical ketoconazole: a systematic review of current dermatological applications and future developments. J Dermatolog Treat. 2019 Dec;30(8):760-771. doi: 10.1080/09546634.2019.1573309. Epub 2019 Feb 14. PMID: 30668185.
  43. Chew SY, Than LT. Vulvovaginal candidosis: contemporary challenges and the future of prophylactic and therapeutic approaches. Mycoses. 2016 May;59(5):262-73. doi: 10.1111/myc.12455. Epub 2016 Jan 13. PMID: 26765516.
  44. Richards JS, JD R. Overview of herbal supplements. Elite Continuing Education. 2013:46-62.
  45. Benitez LL, Carver PL. Adverse Effects Associated with Long-Term Administration of Azole Antifungal Agents. Drugs. 2019 Jun;79(8):833-853. doi: 10.1007/s40265-019-01127-8. PMID: 31093949.
  46. Richards JS, JD R. Overview of herbal supplements. Elite Continuing Education. 2013:46-62.
  47. Bailie GR. Med facts pocket guide of Drug Interactions.
  48. Baxter K, Preston CL, editors. Stockley's drug interactions. London: Pharmaceutical Press; 2010 Jul.
  49. Mutalik M, Sanghavi D. Review of drug interactions: a comprehensive update. Journal of Pharmaceutical Research International. 2014 Mar 12:954-80.
  50. Shafiei M, Peyton L, Hashemzadeh M, Foroumadi A. History of the development of antifungal azoles: A review on structures, SAR, and mechanism of action. Bioorg Chem. 2020 Nov;104:104240. doi: 10.1016/j.bioorg.2020.104240. Epub 2020 Aug 28. PMID: 32906036.
  51. Lakhani P, Patil A, Majumdar S. Challenges in the Polyene- and Azole-Based Pharmacotherapy of Ocular Fungal Infections. J Ocul Pharmacol Ther. 2019 Jan/Feb;35(1):6-22. doi: 10.1089/jop.2018.0089. Epub 2018 Nov 8. PMID: 30481082; PMCID: PMC6354613.
  52. Rauseo AM, Coler-Reilly A, Larson L, Spec A. Hope on the Horizon: Novel Fungal Treatments in Development. Open Forum Infect Dis. 2020 Jan 12;7(2):ofaa016. doi: 10.1093/ofid/ofaa016. PMID: 32099843; PMCID: PMC7031074.
  53. Gupta AK, Stec N, Summerbell RC, Shear NH, Piguet V, Tosti A, Piraccini BM. Onychomycosis: a review. J Eur Acad Dermatol Venereol. 2020 Sep;34(9):1972-1990. doi: 10.1111/jdv.16394. Epub 2020 Jun 5. PMID: 32239567.
  54. Al-Kurjiya DA, Gheorghe I, Popa M, Mihaescu G, Marutescu L. Characterization of non-albicans Candida species involved in human infections. Rom Biotechnol Lett. 2019 Sep 1;24(5):837-44.
  55. AL-Kurjiya DA, Gheorghe I, Popa M, Mihaescu G, Marutescu L. Characterization of non-albicans Candida.
  56. Wilson DT, Dimondi VP, Johnson SW, Jones TM, Drew RH. Role of isavuconazole in the treatment of invasive fungal infections. Ther Clin Risk Manag. 2016 Aug 3;12:1197-206. doi: 10.2147/TCRM.S90335. PMID: 27536124; PMCID: PMC4977098.
  57. Schmiedel Y, Zimmerli S. Common invasive fungal diseases: an overview of invasive candidiasis, aspergillosis, cryptococcosis, and Pneumocystis pneumonia. Swiss Med Wkly. 2016 Feb 22;146:w14281. doi: 10.4414/smw.2016.14281. PMID: 26901377.
  58. McKeny PT, Nessel TA, Zito PM. Antifungal antibiotics. StatPearls [Internet]. 2020 Sep 29.
  59. Nivoix Y, Ledoux MP, Herbrecht R. Antifungal Therapy: New and Evolving Therapies. Semin Respir Crit Care Med. 2020 Feb;41(1):158-174. doi: 10.1055/s-0039-3400291. Epub 2020 Jan 30. PMID: 32000291.
  60. Dymond AW, So K, Martin P, Huang Y, Severin P, Mathews D, Lisbon E, Mariani G. Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials. Eur J Clin Pharmacol. 2017 Feb;73(2):175-184. doi: 10.1007/s00228-016-2153-7. Epub 2016 Nov 26. PMID: 27889832; PMCID: PMC5226997.
  61. Dzintars K, Toman LP. Interpretation and Understanding of Clinical Drug Interactions Between Azoles and Immunosuppressants in Solid Organ Transplant Recipients. Current Fungal Infection Reports. 2020 Aug 6:1-6.
  62. Dzintars K, Toman LP. Interpretation and Understanding of Clinical Drug Interactions Between Azoles and Immunosuppressants in Solid Organ Transplant Recipients. Current Fungal Infection Reports. 2020 Aug 6:1-6.
  63. Wiesner A, Zwolińska-Wcisło M, Paśko P. Effect of Food and Dosing Regimen on Safety and Efficacy of Proton Pump Inhibitors Therapy-A Literature Review. Int J Environ Res Public Health. 2021 Mar 29;18(7):3527. doi: 10.3390/ijerph18073527. PMID: 33805341; PMCID: PMC8036504.
  64. Dodd S, Kollipara S, Sanchez-Felix M, Kim H, Meng Q, Beato S, Heimbach T. Prediction of ARA/PPI Drug-Drug Interactions at the Drug Discovery and Development Interface. J Pharm Sci. 2019 Jan;108(1):87-101. doi: 10.1016/j.xphs.2018.10.032. Epub 2018 Oct 29. PMID: 30385285.
  65. Zhou H, Zhu H. Water-insoluble drugs and their pharmacokinetic behaviors. InWater-Insoluble Drug Formulation 2018 Mar 12;97-111.
  66. Barbosa FD. Aminothioxanthone derivatives: synthesis and study of antifungal synergistic effects.
  67. Chen J, He ZM, Wang FL, Zhang ZS, Liu XZ, Zhai DD, Chen WD. Curcumin and its promise as an anticancer drug: An analysis of its anticancer and antifungal effects in cancer and associated complications from invasive fungal infections. Eur J Pharmacol. 2016 Feb 5;772:33-42. doi: 10.1016/j.ejphar.2015.12.038. Epub 2015 Dec 23. PMID: 26723514.
  68. Seyedmousavi S, Wiederhold NP, Ebel F, Hedayati MT, Rafati H, Verweij PE. Antifungal use in veterinary practice and emergence of resistance. InEmerging and Epizootic Fungal Infections in Animals 2018;359-402.
  69. Seyedmousavi S, Rafati H, Ilkit M, Tolooe A, Hedayati MT, Verweij P. Systemic Antifungal Agents: Current Status and Projected Future Developments. Methods Mol Biol. 2017;1508:107-139. doi: 10.1007/978-1-4939-6515-1_5. PMID: 27837500.
  70. Nett JE, Andes DR. Itraconazole. InKucers’ The Use of Antibiotics 2017 Oct 2;2786-2811.
  71. Rehman K, Kamran SH, Akash MS. Toxicity of antibiotics. InAntibiotics and Antimicrobial Resistance Genes in the Environment 2020 Jan 1;234-252.
  72. Yunihastuti E, Widhani A, Karjadi TH. Drug hypersensitivity in human immunodeficiency virus-infected patient: challenging diagnosis and management. Asia Pac Allergy. 2014 Jan;4(1):54-67. doi: 10.5415/apallergy.2014.4.1.54. Epub 2014 Jan 31. PMID: 24527412; PMCID: PMC3921866.
  73. Megías-Vericat JE, Solana-Altabella A, Ballesta-López O, Martínez-Cuadrón D, Montesinos P. Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia. Ann Hematol. 2020 Sep;99(9):1989-2007. doi: 10.1007/s00277-020-04186-0. Epub 2020 Jul 18. PMID: 32683457.
  74. Rogala BG, Charpentier MM, Nguyen MK, Landolf KM, Hamad L, Gaertner KM. Oral Anticancer Therapy: Management of Drug Interactions. J Oncol Pract. 2019 Feb;15(2):81-90. doi: 10.1200/JOP.18.00483. PMID: 30763198.
  75. Roncato R, Angelini J, Pani A, Cecchin E, Sartore-Bianchi A, Siena S, De Mattia E, Scaglione F, Toffoli G. CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions. Int J Mol Sci. 2020 Sep 1;21(17):6350. doi: 10.3390/ijms21176350. PMID: 32883002; PMCID: PMC7504705.
  76. Ruiz ME, Montoto SS. Routes of drug administration. InADME Processes in Pharmaceutical Sciences 2018;97-133.
  77. Rivosecchi RM, Samanta P, Demehin M, Nguyen MH. Pharmacokinetics of Azole Antifungals in Cystic Fibrosis. Mycopathologia. 2018 Feb;183(1):139-150. doi: 10.1007/s11046-017-0189-6. Epub 2017 Aug 9. PMID: 28795298.
  78. Wu AY, Tseng HK, Liu CP. Prophylactic Strategies for Invasive Fungal Diseases in Hematological Stem Cell Transplantation: An Update. 2018 Feb 1;29(1):38-45.
  79. Nett JE, Andes DR. Antifungal Agents: Spectrum of Activity, Pharmacology, and Clinical Indications. Infect Dis Clin North Am. 2016 Mar;30(1):51-83. doi: 10.1016/j.idc.2015.10.012. Epub 2015 Dec 29. PMID: 26739608.
  80. Lat A, Thompson GR 3rd. Update on the optimal use of voriconazole for invasive fungal infections. Infect Drug Resist. 2011;4:43-53. doi: 10.2147/IDR.S12714. Epub 2011 Feb 3. PMID: 21694908; PMCID: PMC3108750.
  81. Zuckerman JN, Brunette G, Leggat P. Essential travel medicine. John Wiley & Sons; 2015 Jul 20.
  82. Singh B. THE Troubling benzene ring–Its impact on health, crops, drug development, environmental policy-making and the therapeutic challenge.
  83. Roy H, Nandi S. In-Silico Modeling in Drug Metabolism and Interaction: Current Strategies of Lead Discovery. Curr Pharm Des. 2019;25(31):3292-3305. doi: 10.2174/1381612825666190903155935. PMID: 31481001.
  84. Jović Z, Janković SM, Ružić Zečević D, Milovanović D, Stefanović S, Folić M, Milovanović J, Kostić M. Clinical Pharmacokinetics of Second-Generation Triazoles for the Treatment of Invasive Aspergillosis and Candidiasis. Eur J Drug Metab Pharmacokinet. 2019 Apr;44(2):139-157. doi: 10.1007/s13318-018-0513-7. PMID: 30284178.
  85. Amsden JR, Gubbins PO. Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacy. Expert Opin Drug Metab Toxicol. 2017 Nov;13(11):1135-1146. doi: 10.1080/17425255.2017.1391213. Epub 2017 Oct 20. PMID: 29022838.
  86. Bahar MA, Setiawan D, Hak E, Wilffert B. Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6. Pharmacogenomics. 2017 May;18(7):701-739. doi: 10.2217/pgs-2017-0194. Epub 2017 May 8. PMID: 28480783.
  87. Alcazar-Fuoli L, Mellado E. Ergosterol biosynthesis in Aspergillus fumigatus: its relevance as an antifungal target and role in antifungal drug resistance. Front Microbiol. 2013 Jan 10;3:439. doi: 10.3389/fmicb.2012.00439. PMID: 23335918; PMCID: PMC3541703.
  88. Gupta AK, Versteeg SG, Shear NH. Common drug-drug interactions in antifungal treatments for superficial fungal infections. Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):387-398. doi: 10.1080/17425255.2018.1461834. Epub 2018 Apr 26. PMID: 29633864.
  89. Hall GS, Sekeres JA, Neuner E, Hall JO. Antifungal Agents. InInteractions of Yeasts, Moulds, and Antifungal Agents 2012;1-64.
  90. Gupta AK, FOLEY KA. Systemic antifungal agents. Comprehensive dermatologic drug therapy. 2012 Oct 18;3:98-120.
  91. Petersen AB, Rønnest MH, Larsen TO, Clausen MH. The chemistry of griseofulvin. Chem Rev. 2014 Dec 24;114(24):12088-107. doi: 10.1021/cr400368e. Epub 2014 Dec 5. PMID: 25476923.
  92. Leung AK, Lam JM, Leong KF, Hon KL. Tinea corporis: an updated review. Drugs Context. 2020 Jul 20;9:2020-5-6. doi: 10.7573/dic.2020-5-6. PMID: 32742295; PMCID: PMC7375854.
  93. Buckley D. Fungal and Yeast Infection of Skin, Hair and Nails. InTextbook of Primary Care Dermatology 2021;243-249.
  94. Kathiravan MK, Salake AB, Chothe AS, Dudhe PB, Watode RP, Mukta MS, Gadhwe S. The biology and chemistry of antifungal agents: a review. Bioorg Med Chem. 2012 Oct 1;20(19):5678-98. doi: 10.1016/j.bmc.2012.04.045. Epub 2012 May 9. Erratum in: Bioorg Med Chem. 2013 Feb 1;21(3):834. Erratum in: Bioorg Med Chem. 2013 Mar 1;21(5):1367. PMID: 22902032.

Figures:

Figure 1

Figure 1

Figure 1

Figure 2

Figure 1

Figure 3

Figure 1

Figure 4

Figure 1

Figure 5

Figure 1

Figure 6

Figure 1

Figure 7

Figure 1

Figure 8

Figure 1

Figure 9

Figure 1

Figure 10

Figure 1

Figure 11

Figure 1

Figure 12

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More